KRAS and pancreatic ductal adenocarcinoma: The KRAS mutation is a critical determinant in the early stage of pancreatic ductal adenocarcinoma and is able to drive mature pancreatic cells to de‐differentiate into duct‐like cells and, ultimately, PDAC.4 Numerous studies have focused on the role of KRAS mutation in promoting tumorigenesis.